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We have raised four monoclonal antibodies recognizing different epitopes within the human cell-surface receptor for urokinase-type plasminogen 
activator (u-PA). One of these antibodies completely abolishes the potentiation of plasmin generation observed upon incubation of the zymogens 
pro-u-PA and plasminogcn with LJ937 cells. This antibody, which is also the only one to completely inhibit the binding of DFP-inactivated rz51]- 
u-PA to U937 cells, is directed against the u-PA binding NH,-terminal domain of u-PAR. a well-defined fragment formed by limited chymotrypsin 
digestion of pm-ified u-PAR. demonstrating the functional independence of the U-PA binding domain as well as the critical role of u-PAR in the 
assembly of the cell-surface plasminogen activation system. 
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1. INTRODUCTION 
Plasmin, generated from plasminogen by U-PA, is in- 
volved in the degradation of extracellular matrix pro- 
teins in a variety of processes requiring tissue destruc- 
tion or cell migration, including cancer invasion. The 
activity of u-PA is regulated by two fast acting plasmin- 
open activator inhibitors, PAI- and PAI-2, and also 
potentially by a specific cell-surface u-PA receptor (u- 
PAR) [l-3]. 
u-PAR was first detected on monocytes and mono- 
cyte-like cells by a specific, high-affinity binding of u- 
PA 141 and its zymogen pro-u-PA [S], and has since 
been observed on a variety of cultured cells of neo- 
plastic and non-neoplastic origin [6-91. However, the 
existence of additional u-PA-binding molecules on the 
cell surface cannot be excluded [lo-121. We have 
recently purified and characterized u-PAR from PMA- 
treated U937 cells [9,13] and cloned a full-length cDNA 
coding for this receptor [14]. It is an Mr 55-60000 
single-chain highly glycosylated protein which is attach- 
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ed to the plasma membrane by a glycosyl-phosphatidyl- 
inositol lipid anchor [15]. The mature protein consists 
of three homologous internal repeats, each of approx- 
imately 90 amino acids. An isolated NHz-terminal 
chymotryptic fragment, constituting the first of these 
repeats, binds to the receptor-binding part of u-PA in a 
chemical cross-linking assay [ 161. 
The virtually inactive pro-u-PA [17,18] can be con- 
verted to active u-PA while cell-bound [5], and u-PA 
thus bound can activate plasminogen [5,19-211. Con- 
comitant binding of pro-u-PA and plasminogen to cells 
results in a rapid acceleration of plasmin generation 
1191. 
In order to further study structure-function relation- 
ships in the u-PAR molecule and to determine whether 
the binding of u-PA to u-PAR is responsible for the 
cellular potentiation of plasminogen activation, we 
have now developed murine monpclonal antibodies 
against human u-PAR. 
2. EXPERIMENTAL 
2. I. Preparation of monoctonni antibodies 
Purified u-PAR protein [13] was used for immunization of a 
BALB/c mouse, and cells from the spleen and peripheral lymph nodes 
were fused with X63-Ag 8.6.5.3. myeloma cells essentially as describ- 
ed (221. Hybridomas were initially screened by an ELISA, using 2 ng 
purified u-PAR per well in 96.well plates (Flat bottom high binding 
capacity, Nunc). 
Fusion of the spleen (loo0 wells) and lymphnode (90 wells) cells 
resulted in 24 positive hybridomas. Four of these were selected for 
cloning on the basis of criteria including the ability of their condition- 
ed media to react with u-PAR in Western blotting and to inhibit bind- 
ing of [“‘I]ATF to U937 cells. Antibodies from the resulting clones 
were purified on a Protein G-Sepharose column (MAb Trap G, Phar- 
macia). Clones producing antibodies of the indicated subclasses, were 
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designated RI (IgGZb, Kappa), R2 (IgG1, Kappa), R3 (I!&. Kappa) 
and R4 (1gG1, Kappa). A 
2.2. Immunoprecipitation ojpurified u-PAR 
Both ‘*“I-labelled chymotryplic fragments and intact u-PAR [l6] 
were diluted in 0.1 M Tris-HCI, pH 8.1, 0.3 M NaCI, 0.1% MA, 
0.1% CHAPS (reaction buffer) to an activity of 3.5 x Icv’ cpm in 100 
~1 and incubated with an equal volume of each of the monoclonal an- 
tibodies against u-PAR (10 &ml final concentration) or relevant 
controls for 1 h at 4°C. 50 ~1 of a 5O(r/, suspension of Protein A- 
Sepharose CL4B (Pharmacia) in reaction buffer was added and the 
samples incubated for 1 h at 4OC with mixing. The Protein A- 
Sepharose was recovered by centrifugation and washed in reaction 
buffer followed by reaction buffer without BSA. The beads were then 
resuspended in 50 pl SDS-PAGE sample buffer and boiled for 5 min. 
The samples were analyzed by SDS-PAGE in linear 6-16% gradient 
slab gels under non-reducing conditions and autoradiography. 
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2.3. Miscellaneous procedures 
All other materials and procedures were as described [13,19,21]. 
3. RESULTS 
3.1. Differential reactivity of four monoclonal on- 
tibodies against defined proteolytic fragments and 
glycosylation variants of u-PAR 
Fig. 1A shows that each of the four antibodies im- 
munoprecipitates the intact u-PAR molecule. Mild 
chymotrypsin treatment was then used to cleave 
purified u-PAR at a single site into a U-PA binding frag- 
ment of iI& = 16000 and a fragment of iki, 30-50000 
with no u-PA binding activity [la]. The M, J 16000 
chymotryptic fragment was found to be specifically 
precipitated by antibody R3, whereas the RI, R2 and 
R4 antibodies pecifically precipitated the M, 30-50000 
fragment (Fig. 1B). 
We have previously observed that PMA-treated cells 
of the subline U937a have, in addition to the M, 
55-60000 u-PAR protein, a glycosyiation variant with 
an apparent Mr of 40-50000 which is not detected in the 
U937 cell-Iine [IS]. The anti-u-PAR antibodies were 
found to recognize these two glycosylation variants dif- 
ferently in Western blots (data not shown). R2 and R3 
reacted with both glycosylation variants, while R4 
reacted primarily with the lower it& u-PAR variant. 
There was no detectable binding of the Rl antibody to 
either u-PAR variant in Western blotting. 
The reactivity pattern of the antibodies in these ex- 
periments indicates that they recognize different 
epitopes within u-PAR. 
Fig. 1. lmmunoprecipitation of [‘z51]u-PAR and chymotryptic 
fragments by monoclonal antibodies. Purified u-PAR (30 @g/ml) 
from U937 cells was treated with chymotrypsin (40 ng/ml) for 7 h at 
37’C. Both intact u-PAR (I-2 pg) and the chymotryptic fragments of 
u-PAR (l-2 pg) were ‘2SI-labelled and immunoprecipitated, as 
described in section 2. Panel A. lmmunoprecipitation of intact 
[‘251]u-PAR. Lane 1 is [‘*51]u-PAR alone, and lanes 2-7 represent he 
immunoprecipitated material using R2, R3, Rl, R4, a pool of the 4 
monoclonal antibodies, and anti-TNP monoclonal antibody, respec- 
tiveiy. Panel B. lmmunoprecipitation of [‘251]chymotryptic 
fragments of U-PAR. Lane I is [‘251Ju-PAR fragments alone, whereas 
lanes 2-7 represent he immunoprecipitated material using the same 
antibodies as above. The molecular weights of standard proteins are 
indicated. 
3.2. Inhibition of the cell-associated enhancement of 
pro-u-PA-dependent plasminogen activation 
Pro-u-PA dependent plasminogen activation has a partial inhibition of the enhancement of plasmin 
been shown to be greatly enhanced in the presence of generation (Fig. 2D), although this inhibitory effect was 
U937 cells [19]. Fig. 2 demonstrates that preincubation never more than approximately 50% at higher antibody 
of the cells with antibody R3 completely abolished this concentrations (up to 50 pg/ml, data not shown). 
enhancement while the antibodies Rl and R2 were However, if cells which had been pre-incubated with R4 
without any effect. Concentrations of these two an- as before were further incubated with pro-u-PA for 15 
tibodies up to 50 clg/ml were also without effect on the min prior to the addition of plasminogen, the inhibitory 
generation of plasmin in this system. Antibody R4 gave effect of R4 on the enhancement of plasmin generation 
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Fig. 2. The binding of pro-u-PA to cellular u-PAR is essential for enhanced plasmin generation. Acid-washed U937a cells were pre-incubated for 
30 min in the presence or absence of 2 &ml of each of the monoclonal antibodies RI (panel A). R2 (panel B). R3 (panel C), and R4 (panel D), 
prior to incubation with pro-u-PA (1.2 nM), plasminogen 2 (0.14 PM) and the fluorogenic plasmin substrate H-D-Val-Leu- 
Lys-7-amido-4-methylcoumarin (0.2 mM). Plasmin generation was determined from measurements of the rate of change in fluorescence, which 
were compared to calibration curves constructed using active-site titrated plasmin [2l]. Plasmin generation is shown in the absence of cells (v), 
and in the presence of U937a cells pre-incubated with the various antibodies (0) and without antibodies (A). Control experiments howed that 
plasminogen activation in the absence of cells was unaffected by any of the antibodies. 
was abolished. Under the same conditions, the effect of 
antibody R3 as unchanged. 
3 -3. inhibition of u-PA binding to u-PAR on intact cells 
As shown in Fig. 3, the antibody R3 could completely 
abolish the binding of [‘251]DFP-u-PA and subsequent 
formation of cross-linked complex with u-PAR on the 
surface of U937 cells. In contrast, no effect was observ- 
ed with the antibodies R2 and R4 (Fig. 3, lanes 5 and 7), 
and only a slight inhibition of binding with Rl (Fig. 3, 
lane 4). 
4. DISCUSSION 
A previous tudy has shown that the cellular binding 
of pro-u-PA potentiates the plasminogen activation 
system, as concomitant binding of pro-u-PA and 
plasminogen to the cell surface resulted in a rapid ac- 
celeration of plasmin generation [191, The dependence 
of this effect on the cellular binding of pro-u-PA was 
demonstrated by the inhibition of the acceleration by 
ATF, the NHz-terminal fragment of u-PA. It was pro. 
posed that u-PAR was responsible for the potentiation 
on the basis of the following correlations: that ATF 
binds to the cell surface with similar characteristics to
intact u-PA, ATF can be cross-linked to purified u- 
PAR, and that ATF cross-links exclusively. to u-PAR 
on the cell surface. Nevertheless, the dependence of the 
effect on molecules other than u-PAR could not be ex- 
cluded, as the correlation assumes that thz cross-linking 
procedure used is able to detect all interactions between 
ATF and u-PA binding molecules. This is not necessari- 
ly the case, however, as in the murine system, for exipm- 
ple, u-PA is not cross-linked to any cell-surface proteins 
despite its specific cellular binding [8] (Solberg, H. and 
Hoyer-Hansen, G., unpublished). The observation here 
that the antibody R3 completely abolishes the cell- 
induced potentiation of plasmin generation now 
presents directe evidence that this functional effect is 
absolutely dependent upon u-PAR. 
The partial inhibition of the potentiation of plasmin 
generation observed with R4 is apparently contradic- 
tory to its lack of effect on [“‘IJDFP-u-PA binding. 
This is most likely a consequence of the dynamic nature 
of the assay system used to detect cellular plasminogen 
activation, in which we observe not only the enzymatic 
reactions but also the time-dependent cellular binding 
of pro-u-PA and plasminogen. The effect of R4 could 
be explained by an altered rate of association of pro-u- 
PA with u-PAR, possibly caused by steric hindrance, 
which would not be detected in the binding experiments 
performed under equilibrium conditions. The observa- 
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Fig. 3. Inhibition of binding and chemical cross-linking of [‘Z51]DFP- 
U-PA to u-PAR on intact cells by monoclonal antibodies. 5 x 10” 
U937a cells were pre-incubated with buffer alone (lane 3), 25 &ml 
of each of the monoclonal antibodies RI (lane 4), R2 (lane 5). R3 (lane 
6). R4 (lane7) for 1 h at 4”C, followed by the addition of [“‘I]DFP-u- 
PA (final concentration 7nM) and incubation for another hour at the 
same temperature. The cells were then washed 3 times and subjected 
to cross-linking with DSS, followed by 3 washes, Triton X-l 14 lysis, 
SDS-PAGE and autoradiography. Also shown are [‘z51]DFP-~-PA 
without incubation (lane I), [‘z51]DFP-u-PA cross-linked alone (lane 
2), pre-incubation with an excess of cold U-PA (700 nM, lane 9), and 
with a monoclonal antibody of irrelevant specificity (anti-TNP 25 
&ml, lane 8). The u-PA preparation used in this experiment contains 
minor amounts of low molecular weight u-PA (MI 33ooO) and ATF; 
due to the u-PAR binding capacity of ATF, but not of low molecular 
weight u-PA, the following bands are seen after cross-linking; (a) 
cross-linked complex between [‘Z51]DFP-u-PA and U-PAR; (b) cross- 
linked complex between [‘251]ATF and u-PAR; (c) high molecular 
weight [‘z51]DFP-u-PA; (e) [“‘I]ATF. Also indicated are (d) low 
molecular weight [‘Z51]DFP-~-PA, as well as the molecular weights of 
protein standards. 
tion that R4 was without effect on plasmin generation 
when pro-u-PA was pre-incubated with the cells sup- 
ports this view. 
Recent cross-linking studies have shown that a 16 
kDa chymotryptic fragment derived from purified u- 
PAR can bind to u-PA independently of the rest of the 
protein. This fragment includes the NHz-terminus of 
the protein, probably extending to residue 87, and con- 
stitutes the first of three internal repeats in the receptor 
molecule [161. The complete inhibition of [1251]DFP-u- 
PA binding to whole cells by the antibody R3 
demonstrates that this NH2-terminal domain is indeed 
accessible for ligand binding in the membrane- 
associated receptor. The lack of effect of the three other 
monoclonal antibodies, all recognizing different 
epitopes within the rest of the U-PAR molecule, sup- 
ports the view that the two domains constituting this 
part of the molecule do not contribute directly to the 
ligand-binding process. Therefore these observations, 
together with those of the effect of R3 on the potentia- 
tion of plasmin generation, provide independent 
evidence that the NHz-terminal domain of u-PAR con- 
stitutes the functionally distinct ligand binding domain 
of the molecule. 
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